Save

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

PHASE1RECRUITING

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).

Simpliy with AI

Study details:

This study comprises 3 parts:. Part A (Single Ascending Dose \[SAD\]) will be conducted to assess the safety, tolerability, and PK profile in healthy participants following 1 single SC injection of VK2735 or VK2735 matching placebo (SAD Cohort 1 through SAD Cohort 6). Part B (Multiple Ascending Dose \[MAD\]) will be conducted to assess the safety, tolerability, PK and PD profile in otherwise healthy participants who have an increased BMI following single SC injections of VK2735 or matched placebo administered once weekly for 4 consecutive weeks (MAD Cohort 1 through MAD Cohort 5).

Part C (Multiple Ascending Dose \[MAD\], PO) will be conducted to assess the safety, tolerability, PK and PD profiles in otherwise healthy, but obese, participants who have a BMI ≥30 kg/m2 following daily oral administration of VK2735 or matched placebo administered for 28 consecutive days (MAD-PO Cohort 1 through MAD-PO Cohort 4, with optional additional cohorts). Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part A (SAD), Part B (MAD), and Part C (MAD-PO) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Participants must be capable of giving signed informed consent

Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator

Participant body weight must have been stable (no change greater than 5%) for a minimum 8 weeks prior to Screening

Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical study procedures

Willing to comply with contraception requirements

Exclusion criteria

Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history or laboratory testing, as assessed by the PI

Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption

Participants may be excluded from the study if they have conditions that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator

History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant

Use of any investigational drug or product, or participation in an investigational drug study within 30 days prior to dosing or 5 half-lives of the drug (whichever is longest)

Active smoker and/or user of nicotine-containing products unless the participant agrees to discontinue smoking/use of nicotine-containing products from 2 weeks before first IP dose administration through to study completion, including the Follow-up period

Have serum triglycerides > 5.65 mmol/L (500 mg/dL) at Screening

Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or HIV

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : Yes

Gender eligible for study: All

Things to know

Study dates

Study start: 2021-12-14

Primary completion: 2023-11-01

Study completion finish: 2023-12-01

Study type

TREATMENT

Phase

PHASE1

Trial ID

NCT05203237

Intervention or treatment

BIOLOGICAL: VK2735

BIOLOGICAL: Placebo

DRUG: VK2735 Placebo

DRUG: VK2735 Drug

Conditions

• NASH
• Weight Loss

Condition: NASH, Weight Loss
BIOLOGICAL: VK2735 and other drugs
Adelaide, South Australia, Australia
Sponsor: Viking Therapeutics, Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Viking Clinical Site

Research sites nearby

Select from list below to view details:

Viking Clinical Site
Adelaide, South Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
PLACEBO_COMPARATOR: Placebo (Part A) Placebo administered SC once in healthy participants	BIOLOGICAL: Placebo Administered SC
EXPERIMENTAL: VK2735 (Part A) Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.	BIOLOGICAL: VK2735 Administered SC
PLACEBO_COMPARATOR: Placebo (Part B) Placebo administered SC once weekly for four weeks in healthy participants	BIOLOGICAL: Placebo Administered SC
EXPERIMENTAL: VK2735 (Part B) Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.	BIOLOGICAL: VK2735 Administered SC
PLACEBO_COMPARATOR: VK2735 (Part C ) Placebo administered orally daily for 28 days in healthy participants	DRUG: VK2735 Placebo Administered orally
EXPERIMENTAL: VK2735 (Part C) Escalating doses of VK2735 administered daily (PO) in healthy participants.	DRUG: VK2735 Drug Administered orally

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)	To evaluate the safety and tolerability of single doses of subcutaneous injections of VK2735 in healthy participants	8 days

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Evaluate the Pharmacokinetic profile of VK2735	Pharmacokinetic profile of VK2735 by measuring peak plasma concentration (Cmax)	29 days

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Phase 1 Study to Evaluate the Safety and Tolerability of VK2735